Literature DB >> 27872090

Mutational Landscape of Pediatric Acute Lymphoblastic Leukemia.

Ling-Wen Ding1, Qiao-Yang Sun1, Kar-Tong Tan1, Wenwen Chien1, Anand Mayakonda1, Allen Eng Juh Yeoh1, Norihiko Kawamata2,3, Yasunobu Nagata4, Jin-Fen Xiao1, Xin-Yi Loh1, De-Chen Lin1,3, Manoj Garg1, Yan-Yi Jiang1, Liang Xu1, Su-Lin Lim1, Li-Zhen Liu1, Vikas Madan1, Masashi Sanada4, Lucia Torres Fernández1, S S Hema Preethi1, Michael Lill3, Hagop M Kantarjian5, Steven M Kornblau5, Satoru Miyano6,7, Der-Cherng Liang8, Seishi Ogawa4, Lee-Yung Shih9, Henry Yang1, H Phillip Koeffler1,3.   

Abstract

Current standard of care for patients with pediatric acute lymphoblastic leukemia (ALL) is mainly effective, with high remission rates after treatment. However, the genetic perturbations that give rise to this disease remain largely undefined, limiting the ability to address resistant tumors or develop less toxic targeted therapies. Here, we report the use of next-generation sequencing to interrogate the genetic and pathogenic mechanisms of 240 pediatric ALL cases with their matched remission samples. Commonly mutated genes fell into several categories, including RAS/receptor tyrosine kinases, epigenetic regulators, transcription factors involved in lineage commitment, and the p53/cell-cycle pathway. Unique recurrent mutational hotspots were observed in epigenetic regulators CREBBP (R1446C/H), WHSC1 (E1099K), and the tyrosine kinase FLT3 (K663R, N676K). The mutant WHSC1 was established as a gain-of-function oncogene, while the epigenetic regulator ARID1A and transcription factor CTCF were functionally identified as potential tumor suppressors. Analysis of 28 diagnosis/relapse trio patients plus 10 relapse cases revealed four evolutionary paths and uncovered the ordering of acquisition of mutations in these patients. This study provides a detailed mutational portrait of pediatric ALL and gives insights into the molecular pathogenesis of this disease. Cancer Res; 77(2); 390-400. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2016        PMID: 27872090      PMCID: PMC5243866          DOI: 10.1158/0008-5472.CAN-16-1303

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  50 in total

1.  Oncogenically active MYD88 mutations in human lymphoma.

Authors:  Vu N Ngo; Ryan M Young; Roland Schmitz; Sameer Jhavar; Wenming Xiao; Kian-Huat Lim; Holger Kohlhammer; Weihong Xu; Yandan Yang; Hong Zhao; Arthur L Shaffer; Paul Romesser; George Wright; John Powell; Andreas Rosenwald; Hans Konrad Muller-Hermelink; German Ott; Randy D Gascoyne; Joseph M Connors; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; Jan Delabie; Erlend B Smeland; Richard I Fisher; Rita M Braziel; Raymond R Tubbs; J R Cook; Denny D Weisenburger; Wing C Chan; Louis M Staudt
Journal:  Nature       Date:  2010-12-22       Impact factor: 49.962

2.  Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia.

Authors:  Huining Kang; I-Ming Chen; Carla S Wilson; Edward J Bedrick; Richard C Harvey; Susan R Atlas; Meenakshi Devidas; Charles G Mullighan; Xuefei Wang; Maurice Murphy; Kerem Ar; Walker Wharton; Michael J Borowitz; W Paul Bowman; Deepa Bhojwani; William L Carroll; Bruce M Camitta; Gregory H Reaman; Malcolm A Smith; James R Downing; Stephen P Hunger; Cheryl L Willman
Journal:  Blood       Date:  2009-10-30       Impact factor: 22.113

3.  RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia.

Authors:  Elli Papaemmanuil; Inmaculada Rapado; Yilong Li; Nicola E Potter; David C Wedge; Jose Tubio; Ludmil B Alexandrov; Peter Van Loo; Susanna L Cooke; John Marshall; Inigo Martincorena; Jonathan Hinton; Gunes Gundem; Frederik W van Delft; Serena Nik-Zainal; David R Jones; Manasa Ramakrishna; Ian Titley; Lucy Stebbings; Catherine Leroy; Andrew Menzies; John Gamble; Ben Robinson; Laura Mudie; Keiran Raine; Sarah O'Meara; Jon W Teague; Adam P Butler; Giovanni Cazzaniga; Andrea Biondi; Jan Zuna; Helena Kempski; Markus Muschen; Anthony M Ford; Michael R Stratton; Mel Greaves; Peter J Campbell
Journal:  Nat Genet       Date:  2014-01-12       Impact factor: 38.330

4.  Clonal origins of ETV6-RUNX1⁺ acute lymphoblastic leukemia: studies in monozygotic twins.

Authors:  D Alpar; D Wren; L Ermini; M B Mansur; F W van Delft; C M Bateman; I Titley; L Kearney; T Szczepanski; D Gonzalez; A M Ford; N E Potter; M Greaves
Journal:  Leukemia       Date:  2014-11-12       Impact factor: 11.528

5.  Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome.

Authors:  Richard C Harvey; Charles G Mullighan; Xuefei Wang; Kevin K Dobbin; George S Davidson; Edward J Bedrick; I-Ming Chen; Susan R Atlas; Huining Kang; Kerem Ar; Carla S Wilson; Walker Wharton; Maurice Murphy; Meenakshi Devidas; Andrew J Carroll; Michael J Borowitz; W Paul Bowman; James R Downing; Mary Relling; Jun Yang; Deepa Bhojwani; William L Carroll; Bruce Camitta; Gregory H Reaman; Malcolm Smith; Stephen P Hunger; Cheryl L Willman
Journal:  Blood       Date:  2010-08-10       Impact factor: 22.113

6.  Exome sequencing identifies recurring FLT3 N676K mutations in core-binding factor leukemia.

Authors:  Sabrina Opatz; Harald Polzer; Tobias Herold; Nikola P Konstandin; Bianka Ksienzyk; Evelyn Zellmeier; Sebastian Vosberg; Alexander Graf; Stefan Krebs; Helmut Blum; Karl-Peter Hopfner; Purvi M Kakadia; Stephanie Schneider; Annika Dufour; Jan Braess; Maria Cristina Sauerland; Wolfgang E Berdel; Thomas Büchner; Bernhard J Woermann; Wolfgang Hiddemann; Karsten Spiekermann; Stefan K Bohlander; Philipp A Greif
Journal:  Blood       Date:  2013-07-22       Impact factor: 22.113

Review 7.  Clonal evolution in hematological malignancies and therapeutic implications.

Authors:  D A Landau; S L Carter; G Getz; C J Wu
Journal:  Leukemia       Date:  2013-08-27       Impact factor: 11.528

8.  Inactivating mutations of acetyltransferase genes in B-cell lymphoma.

Authors:  Laura Pasqualucci; David Dominguez-Sola; Annalisa Chiarenza; Giulia Fabbri; Adina Grunn; Vladimir Trifonov; Lawryn H Kasper; Stephanie Lerach; Hongyan Tang; Jing Ma; Davide Rossi; Amy Chadburn; Vundavalli V Murty; Charles G Mullighan; Gianluca Gaidano; Raul Rabadan; Paul K Brindle; Riccardo Dalla-Favera
Journal:  Nature       Date:  2011-03-10       Impact factor: 49.962

9.  Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia.

Authors:  Julia A Meyer; Jinhua Wang; Laura E Hogan; Jun J Yang; Smita Dandekar; Jay P Patel; Zuojian Tang; Paul Zumbo; Sheng Li; Jiri Zavadil; Ross L Levine; Timothy Cardozo; Stephen P Hunger; Elizabeth A Raetz; William E Evans; Debra J Morrison; Christopher E Mason; William L Carroll
Journal:  Nat Genet       Date:  2013-02-03       Impact factor: 38.330

10.  Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia.

Authors:  Brenton G Mar; Lars B Bullinger; Kathleen M McLean; Peter V Grauman; Marian H Harris; Kristen Stevenson; Donna S Neuberg; Amit U Sinha; Stephen E Sallan; Lewis B Silverman; Andrew L Kung; Luca Lo Nigro; Benjamin L Ebert; Scott A Armstrong
Journal:  Nat Commun       Date:  2014-03-24       Impact factor: 14.919

View more
  34 in total

Review 1.  Using genomics to define pediatric blood cancers and inform practice.

Authors:  Rachel E Rau; Mignon L Loh
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

2.  Mutational and transcriptomic profiling of acute leukemia of ambiguous lineage reveals obscure but clinically important lineage bias.

Authors:  Zhen-Tang Lao; Ling-Wen Ding; Omer An; Norimichi Hattori; Qiao-Yang Sun; Kar-Tong Tan; Anand Mayakonda; Wong Gee Chuan; Vikas Madan; De-Chen Lin; Henry Yang; H Phillip Koeffler
Journal:  Haematologica       Date:  2018-12-04       Impact factor: 9.941

3.  Pediatric ALL relapses after allo-SCT show high individuality, clonal dynamics, selective pressure, and druggable targets.

Authors:  Jessica I Hoell; Sebastian Ginzel; Michaela Kuhlen; Andreas Kloetgen; Michael Gombert; Ute Fischer; Daniel Hein; Salih Demir; Martin Stanulla; Martin Schrappe; Udo Zur Stadt; Peter Bader; Florian Babor; Friedhelm Schuster; Brigitte Strahm; Julia Alten; Anja Moericke; Gabriele Escherich; Arend von Stackelberg; Ralf Thiele; Alice C McHardy; Christina Peters; Beat Bornhauser; Jean-Pierre Bourquin; Stefan Krause; Juergen Enczmann; Lüder Hinrich Meyer; Cornelia Eckert; Arndt Borkhardt; Roland Meisel
Journal:  Blood Adv       Date:  2019-10-22

4.  Defining the NSD2 interactome: PARP1 PARylation reduces NSD2 histone methyltransferase activity and impedes chromatin binding.

Authors:  Xiaoxiao Huang; Richard D LeDuc; Luca Fornelli; Alissa J Schunter; Richard L Bennett; Neil L Kelleher; Jonathan D Licht
Journal:  J Biol Chem       Date:  2019-06-27       Impact factor: 5.157

Review 5.  Emerging themes in cohesin cancer biology.

Authors:  Todd Waldman
Journal:  Nat Rev Cancer       Date:  2020-06-08       Impact factor: 60.716

6.  The NSD2 p.E1099K Mutation Is Enriched at Relapse and Confers Drug Resistance in a Cell Context-Dependent Manner in Pediatric Acute Lymphoblastic Leukemia.

Authors:  Joanna Pierro; Jason Saliba; Sonali Narang; Gunjan Sethia; Shella Saint Fleur-Lominy; Ashfiyah Chowdhury; Anita Qualls; Hannah Fay; Harrison L Kilberg; Takaya Moriyama; Tori J Fuller; David T Teachey; Kjeld Schmiegelow; Jun J Yang; Mignon L Loh; Patrick A Brown; Jinghui Zhang; Xiaotu Ma; Aristotelis Tsirigos; Nikki A Evensen; William L Carroll
Journal:  Mol Cancer Res       Date:  2020-04-24       Impact factor: 5.852

7.  Genetic variants and clinical significance of pediatric acute lymphoblastic leukemia.

Authors:  Hong-Hong Zhang; Hong-Sheng Wang; Xiao-Wen Qian; Cui-Qing Fan; Jun Li; Hui Miao; Xiao-Hua Zhu; Yi Yu; Jian-Hua Meng; Ping Cao; Jun Le; Jun-Ye Jiang; Wen-Jing Jiang; Ping Wang; Xiao-Wen Zhai
Journal:  Ann Transl Med       Date:  2019-07

Review 8.  A rare subgroup of leukemia stem cells harbors relapse-inducing potential in acute lymphoblastic leukemia.

Authors:  Daniela Senft; Irmela Jeremias
Journal:  Exp Hematol       Date:  2018-09-24       Impact factor: 3.084

9.  Application of targeted next generation sequencing for the mutational profiling of patients with acute lymphoblastic leukemia.

Authors:  Dragana Janic; Jelena Peric; Teodora Karan-Djurasevic; Tatjana Kostic; Irena Marjanovic; Bojana Stanic; Nadja Pejanovic; Lidija Dokmanovic; Jelena Lazic; Nada Krstovski; Marijana Virijevic; Dragica Tomin; Ana Vidovic; Nada Suvajdzic-Vukovic; Sonja Pavlovic; Natasa Tosic
Journal:  J Med Biochem       Date:  2020-01-10       Impact factor: 3.402

Review 10.  Drug repurposing for targeting cyclic nucleotide transporters in acute leukemias - A missed opportunity.

Authors:  Dominique R Perez; Larry A Sklar; Alexandre Chigaev; Ksenia Matlawska-Wasowska
Journal:  Semin Cancer Biol       Date:  2020-02-07       Impact factor: 15.707

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.